Canadian manufacturer Medicago's COVID-19 vaccine showing strong efficacy | Globalnews.ca - Globalnews.ca | Canada News Media
Connect with us

Business

Canadian manufacturer Medicago's COVID-19 vaccine showing strong efficacy | Globalnews.ca – Globalnews.ca

Published

 on


A home-grown COVID-19 vaccine candidate could soon be on the market, with Quebec-based Medicago’s latest data showing promising results. The biopharmaceutical manufacturer, which says its product showed 75.3 per cent efficacy against the Delta variant, said it plans to “imminently” file a final regulatory submission to Health Canada.

“I think the results that we have are really exciting and really interesting,” said Brian Ward, medical officer for Medicago.

The data published by Medicago showed efficacy against COVID-19 variants, such as Delta, which is globally the dominant strain. The company said in a press release that other vaccines which are currently in use did not have Phase 3 trials with the Delta variant. Overall, the vaccine had a 71 per cent efficacy against all variants, but the trials occurred before the appearance of the largely unknown Omicron variant.

“Our vaccine was actually challenged by these much more complicated, mutated viruses,” Ward said. “The overall efficacy that we achieved (in) that changed environment was actually really exciting for us.”

Read more:

Medicago clinical trial participants want equal access to Quebec COVID-19 vaccine passport

The vaccine, which is plant-based, “uses living plants as bioreactors to produce a non-infectious particle that mimics the target virus, without the use of any viruses,” according to the company. The technology produces Virus-Like Particles (VLP) for the protein vaccines, which mimic the actual coronavirus and can be easily picked up by the immune system. VLPs are not infectious and unable to replicated.

Medicago’s COVID-19 vaccine uses an adjuvant, which is a drug, substance or combination of substances used to amplify a vaccine effectiveness. Ward said Medicago’s vaccine candidate will also come with a lot of firsts.

“It will probably be the first virus-like particle vaccine for COVID,  the first Canadian based vaccine for COVID, and it will be the world’s first plant-based vaccine for human use of any kind,” he said.






2:00
Plants key for Canada’s COVID-19 vaccine contender


Plants key for Canada’s COVID-19 vaccine contender – Jan 11, 2021

No serious adverse events were reported during the trials and the Medicago’s trials, which took place in six countries, saw over 24,000 participants participate. Half used the Canadian company’s vaccine candidate with the others using a placebo. The subjects were all 18 and older and were given two doses of the vaccine 21 days apart.

Read more:

Canada’s Medicago says its COVID-19 vaccine shows promising antibody results in trial

Innovation Minister Francois-Philippe Champagne told the Canadian Press that he was impressed by how Canada has built up vaccine manufacturing infrastructure in a short time. The Canadian government has invested $173 million in Medicago’s vaccine candidate. Medicago’s current production facility is based in North Carolina, but the company is in the midst of building a global production facility in Quebec by the end of 2023.

“We’re seeing a renewed interest in bringing some of that (manufacturing) capacity back into the country,” Ward said. “I think there is a commitment.”

The vaccine was developed in partnership with Medicago British-American vaccine giant GlaxoSmithKline (GSK). For Ward, the phase 3 results show the power of Canadian ingenuity and research if provided the correct resources.

“We’re a small group of people, we’re a small company. And I think probably by a fair stretch we’re one of the smallest companies to successfully run a study of this size and complexity,” he said.






4:28
The made-in-Quebec COVID-19 vaccine


The made-in-Quebec COVID-19 vaccine – Jan 14, 2021

The landscape for vaccines in Canada has shifted from earlier in the pandemic when the country was struggling to secure doses. Now, with over 80 per cent of the population fully vaccinated and vaccines going to waste, Ward thinks Medicago’s vaccine candidate can play a role domestically, albeit a small one.

“Vaccine booster doses are needed to protect people,” Ward said. “There is data that shows mixing vaccines work well, too. I see that being the Canadian application.”

Canada’s National Advisory Committee on Immunization has “strongly” recommended a COVID-19 vaccine booster shot for people 50 and older. The committee also recommended that booster shots of an mRNA vaccine be offered to adults ages 18 to 49 at least six months after their second dose.

Read more:

Canada’s COVID-19 vaccine contender: Medicago’s breakthrough, ties to Big Tobacco and warnings a pandemic was coming

Health Canada does have an agreement in place with Medicago for an initial purchase of 20 million doses with an ability to increase to 76 million, if needed. But, to Ward and Medicago, they think that their best way forward will be to provide global vaccine relief after receiving authorization.

“There is a global need for vaccines,” Ward said. “Less than one half of the world’s population has had access to vaccines so far so that there are still billions of doses that are needed. We would like to be able to contribute.”

Even the vaccines produced for Canadians can be used globally depending on the discretion of the federal government, according to Ward.

“Canada would make the decision on how to use those vaccines, and we are in negotiation with other countries,” he said.

with files from the Canadian Press

© 2021 Global News, a division of Corus Entertainment Inc.

Adblock test (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version